What was the overall market valuation of the US renal cancer-drug market in 2024?

The overall market valuation was $3970.0 Million in 2024. Read More

What is the projected market valuation for the US renal cancer-drug market by 2035?

The projected valuation for 2035 is $6030.0 Million. Read More

What is the expected CAGR for the US renal cancer-drug market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 3.87%. Read More

Which companies are considered key players in the US renal cancer-drug market?

Key players include Bristol-Myers Squibb, Roche, Merck & Co, Novartis, Pfizer, AstraZeneca, Eli Lilly and Company, Bayer, and Amgen. Read More

What are the main therapeutic areas within the US renal cancer-drug market?

The main therapeutic areas include Targeted Therapy, Immunotherapy, and Chemotherapy. Read More

What was the market value for Targeted Therapy in the US renal cancer-drug market in 2024?

The market value for Targeted Therapy was $1580.0 Million in 2024. Read More

What is the projected market value for Immunotherapy by 2035?

The projected market value for Immunotherapy by 2035 is $1800.0 Million. Read More

Which drug classes are prominent in the US renal cancer-drug market?

Prominent drug classes include Monoclonal Antibodies, Tyrosine Kinase Inhibitors, Checkpoint Inhibitors, and Chemotherapeutic Agents. Read More

What is the expected market value for Oral administration routes in the US renal cancer-drug market by 2035?

The expected market value for Oral administration routes by 2035 is $2390.0 Million. Read More

What are the primary end users of renal cancer drugs in the US market?

Primary end users include Hospitals, Oncology Clinics, and Research Institutions. Read More

US Renal Cancer Drug Market

ID: MRFR/Pharma/15198-HCR

100 Pages

Satyendra Maurya

Last Updated: April 06, 2026

US Renal Cancer Drug Market Research Report By Drug Type (Targeted Therapy, Immunotherapy, Chemotherapy, Hormonal Therapy), By Administration Route (Oral, Intravenous, Subcutaneous), By Indication (Clear Cell Carcinoma, Papillary Carcinoma, Chromophobe Carcinoma) and By Patient Type (Adult Patients, Pediatric Patients) - Growth & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Food, Beverages & Nutrition, BY Therapeutic Areas (USD Million)
  1. 4.1.1 Targeted Therapy
  2. 4.1.2 Immunotherapy
  3. 4.1.3 Chemotherapy
2. 4.2 Food, Beverages & Nutrition, BY Drug Class (USD Million)
  1. 4.2.1 Monoclonal Antibodies
  2. 4.2.2 Tyrosine Kinase Inhibitors
  3. 4.2.3 Checkpoint Inhibitors
  4. 4.2.4 Chemotherapeutic Agents
3. 4.3 Food, Beverages & Nutrition, BY Administration Route (USD Million)
  1. 4.3.1 Oral
  2. 4.3.2 Intravenous
  3. 4.3.3 Subcutaneous
4. 4.4 Food, Beverages & Nutrition, BY End User (USD Million)
  1. 4.4.1 Hospitals
  2. 4.4.2 Oncology Clinics
  3. 4.4.3 Research Institutions
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Food, Beverages & Nutrition
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Food, Beverages & Nutrition
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Bristol-Myers Squibb (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Roche (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Merck & Co (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Novartis (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Pfizer (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 AstraZeneca (GB)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Eli Lilly and Company (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Bayer (DE)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Amgen (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY THERAPEUTIC AREAS
3. 6.3 US MARKET ANALYSIS BY DRUG CLASS
4. 6.4 US MARKET ANALYSIS BY ADMINISTRATION ROUTE
5. 6.5 US MARKET ANALYSIS BY END USER
6. 6.6 KEY BUYING CRITERIA OF FOOD, BEVERAGES & NUTRITION
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF FOOD, BEVERAGES & NUTRITION
9. 6.9 DRIVERS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
10. 6.10 RESTRAINTS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
11. 6.11 SUPPLY / VALUE CHAIN: FOOD, BEVERAGES & NUTRITION
12. 6.12 FOOD, BEVERAGES & NUTRITION, BY THERAPEUTIC AREAS, 2024 (% SHARE)
13. 6.13 FOOD, BEVERAGES & NUTRITION, BY THERAPEUTIC AREAS, 2024 TO 2035 (USD Million)
14. 6.14 FOOD, BEVERAGES & NUTRITION, BY DRUG CLASS, 2024 (% SHARE)
15. 6.15 FOOD, BEVERAGES & NUTRITION, BY DRUG CLASS, 2024 TO 2035 (USD Million)
16. 6.16 FOOD, BEVERAGES & NUTRITION, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
17. 6.17 FOOD, BEVERAGES & NUTRITION, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Million)
18. 6.18 FOOD, BEVERAGES & NUTRITION, BY END USER, 2024 (% SHARE)
19. 6.19 FOOD, BEVERAGES & NUTRITION, BY END USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY THERAPEUTIC AREAS, 2025-2035 (USD Million)
  2. 7.2.2 BY DRUG CLASS, 2025-2035 (USD Million)
  3. 7.2.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
  4. 7.2.4 BY END USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Food, Beverages & Nutrition Market Segmentation

Food, Beverages & Nutrition By Therapeutic Areas (USD Million, 2025-2035)

Targeted Therapy
Immunotherapy
Chemotherapy

Food, Beverages & Nutrition By Drug Class (USD Million, 2025-2035)

Monoclonal Antibodies
Tyrosine Kinase Inhibitors
Checkpoint Inhibitors
Chemotherapeutic Agents

Food, Beverages & Nutrition By Administration Route (USD Million, 2025-2035)

Oral
Intravenous
Subcutaneous

Food, Beverages & Nutrition By End User (USD Million, 2025-2035)

Hospitals
Oncology Clinics
Research Institutions

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”